Factor 1 Protein Enhances Angiogenesis and Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myocardial infarction (AMI) are limited, and there is a need for drugs that can promote healing and angiogenesis without using bone marrow cells, as existing therapies mainly focus on reperfusion and medication without direct cardiac repair mechanisms.
Innovation Solution
Development of proteins, specifically Factor 1 and Factor 2, encoded by nucleic acids derived from the human chromosomal region C19Orf10 and C19Orf63, which exhibit anti-apoptotic and pro-angiogenic properties, used as medicaments to enhance tissue repair and proliferation in the heart after AMI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow cells are used for direct repair of heart muscle, then tissue repair and regeneration are improved, but treatment complexity and invasiveness increase
Solution Approach 1:
The patent extracts and isolates specific secreted proteins (Factor 1 and Factor 2) from bone marrow cells, separating the therapeutic active components from the complex cellular structure. This allows the therapeutic effects to be delivered without using whole bone marrow cells, thereby reducing treatment complexity while maintaining repair effectiveness
Solution Approach 2:
The secreted proteins identified in the patent act as intermediary substances that mediate the repair process. Instead of directly transplanting bone marrow cells, the patent uses these protein factors as intermediaries to stimulate endogenous repair mechanisms, simplifying the treatment approach while preserving therapeutic benefits
2Productivity
If reperfusion therapy is administered to open occluded coronary arteries, then blood flow restoration is improved, but reperfusion injury and mortality risk increase
Solution Approach 1:
The patent identifies secreted proteins that can be administered before or during reperfusion therapy to preemptively counteract the harmful effects of reperfusion injury. These proteins prepare the tissue to withstand the stress of restored blood flow, reducing damage while maintaining the benefits of reperfusion
Solution Approach 2:
The patent converts the harmful reperfusion injury process into a beneficial outcome by using secreted proteins to modulate the reperfusion response. The same physiological process that causes injury is redirected to promote protective and reparative effects through protein-mediated signaling pathways
3Reliability
If thrombocyte aggregation inhibitors and coagulation inhibitors are administered to prevent vessel reclosure, then vessel patency is improved, but bleeding risk increases
Solution Approach 1:
The patent employs secreted proteins that exert their anti-aggregation and anti-coagulation effects locally at the site of the occluded vessel through paracrine signaling. This localized action maintains vessel patency where needed while minimizing systemic bleeding risks, as the therapeutic effect is concentrated at the target site rather than affecting the entire circulation system
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3B
AI summary
The present invention relates to proteins comprising amino acid sequences encoded by nucleic acids derived from the human chromosomal region C19Orf10 termed Factor1 and/or C19Orf63 termed Factor 2 for the use in enhancing proliferation and/or healing and/or inhibiting apoptosis of none-transformed tissue or none-transformed cell or inhibitors thereof. The invention further relates to the use of inhibitors of factor1 and factor 2 for medical use, preferably for use in treating or preventing a disease in which angiogenesis contributes to disease development or progression.